5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Yasuteru, Ngwe Tun, Mya Myat, Kurosaki, Yohei, Sakura, Takaya, Inaoka, Daniel Ken, Fujine, Kiyotaka, Kita, Kiyoshi, Morita, Kouichi, Yasuda, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846235/
https://www.ncbi.nlm.nih.gov/pubmed/33571909
http://dx.doi.org/10.1016/j.bbrc.2021.01.091
_version_ 1783644699070824448
author Sakurai, Yasuteru
Ngwe Tun, Mya Myat
Kurosaki, Yohei
Sakura, Takaya
Inaoka, Daniel Ken
Fujine, Kiyotaka
Kita, Kiyoshi
Morita, Kouichi
Yasuda, Jiro
author_facet Sakurai, Yasuteru
Ngwe Tun, Mya Myat
Kurosaki, Yohei
Sakura, Takaya
Inaoka, Daniel Ken
Fujine, Kiyotaka
Kita, Kiyoshi
Morita, Kouichi
Yasuda, Jiro
author_sort Sakurai, Yasuteru
collection PubMed
description The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
format Online
Article
Text
id pubmed-7846235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78462352021-02-01 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro Sakurai, Yasuteru Ngwe Tun, Mya Myat Kurosaki, Yohei Sakura, Takaya Inaoka, Daniel Ken Fujine, Kiyotaka Kita, Kiyoshi Morita, Kouichi Yasuda, Jiro Biochem Biophys Res Commun Article The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19. Elsevier Inc. 2021-03-19 2021-01-29 /pmc/articles/PMC7846235/ /pubmed/33571909 http://dx.doi.org/10.1016/j.bbrc.2021.01.091 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sakurai, Yasuteru
Ngwe Tun, Mya Myat
Kurosaki, Yohei
Sakura, Takaya
Inaoka, Daniel Ken
Fujine, Kiyotaka
Kita, Kiyoshi
Morita, Kouichi
Yasuda, Jiro
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title_full 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title_fullStr 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title_full_unstemmed 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title_short 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
title_sort 5-amino levulinic acid inhibits sars-cov-2 infection in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846235/
https://www.ncbi.nlm.nih.gov/pubmed/33571909
http://dx.doi.org/10.1016/j.bbrc.2021.01.091
work_keys_str_mv AT sakuraiyasuteru 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT ngwetunmyamyat 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT kurosakiyohei 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT sakuratakaya 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT inaokadanielken 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT fujinekiyotaka 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT kitakiyoshi 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT moritakouichi 5aminolevulinicacidinhibitssarscov2infectioninvitro
AT yasudajiro 5aminolevulinicacidinhibitssarscov2infectioninvitro

Ejemplares similares